Bioburden – ISO 11737-1

What Is Bioburden — ISO 11737-1?

The bioburden test determines the number and nature of the viable microorganism population present on the product before sterilisation. Since determining the sterilisation dose and process depends directly on bioburden, it is a fundamental input to sterilisation validation.

Purpose of Bioburden — ISO 11737-1

The purpose is to produce the microbiological baseline data required for designing and verifying the sterilisation process, and to monitor the continuity of manufacturing hygiene.

Which Products Is Bioburden — ISO 11737-1 Applied To?

Pre-sterilisation medical devices
Implants and surgical instruments
Single-use sets
Sterile-packaging components
Wound-care products

In Which Sectors Is Bioburden — ISO 11737-1 Used?

Medical DeviceHealthcarePharmaceuticals

Standards Related to Bioburden — ISO 11737-1

ISO 11737-1determination of microbial load in medical devices test

Bioburden — ISO 11737-1 Conditions

Recovery: The method of removing microorganisms from the specimen (shaking, sonication, rinsing) must be validated
Recovery efficiency: How much microorganism the method recovers is determined and applied to the result as a correction factor
Culture media: Separate culture media and incubation conditions for bacterial and fungal counts

Equipment for Bioburden — ISO 11737-1

Sonicator and shaker
Membrane filtration unit
Incubators
Colony counting system
Biosafety cabinet

Sample Requirements for Bioburden — ISO 11737-1

Product taken from the production line, before sterilisation
The number of specimens is determined per ISO 11737-1
The sampling date, line and batch information must be recorded
Specimens must be transported under conditions that do not allow microbial growth

Duration of Bioburden — ISO 11737-1

The initial study, including the recovery study, takes several weeks; routine monitoring results are obtained within days, depending on the incubation period.

Bioburden — ISO 11737-1 Procedure

1The recovery method is selected and its efficiency is determined.
2Specimens are taken under aseptic conditions.
3Microorganisms are removed from the product.
4The resulting liquid is inoculated into culture media or filtered.
5It is incubated at the appropriate temperature and duration.
6Colonies are counted and corrected by the recovery factor.
7The result is reported as CFU per product.

Bioburden — ISO 11737-1 Acceptance Criteria

The bioburden test has no acceptance limit of its own; the result is an input. The organisation defines an alert and action limit for the bioburden level used in sterilisation validation, and compares routine results against these limits.

Evaluation of Results

Results are evaluated as a trend over time. An increase in bioburden may require re-evaluation of the sterilisation dose; routine monitoring is therefore part of maintaining sterilisation validity.

Bioburden — ISO 11737-1 Report

Standard and method applied
Specimen description, batch and sampling date
Recovery method and efficiency factor
Culture media and incubation conditions
CFU results per product
Comparison with alert/action limits

Accreditation

EUROLAB holds internationally recognised accreditation obtained from accreditation bodies party to the IAF and ILAC multilateral recognition arrangements, under ISO/IEC 17025 for laboratory testing, ISO/IEC 17020 for inspection and surveillance, and ISO/IEC 17021-1 and ISO/IEC 17065 for system and product certification. This chain ensures the reports and certificates issued are accepted worldwide.

Whether this test can be offered within accredited scope depends on your product and the standard applied; since accreditation is method-based, the scope is confirmed in writing at the quotation stage.

Scope and authorisations

Related Regulations

MDR (EU) 2017/745
ISO 11135 / ISO 11137

Medikal Cihaz Testleri — What Does This Testing Field Cover?

The section below describes the field that the Bioburden test belongs to; the conditions and acceptance criteria of this particular test are given in the sections above. The scope specific to your product is confirmed in writing at the quotation stage.

Medical device testing shows that a device is safe for the patient and the user and maintains its intended performance. In this family safety is not only about avoiding harm; a device failing to perform its expected function is also treated as a risk. A monitor missing an alarm or a pump delivering the wrong dose is directly a patient safety event.

At the centre of the field is RISK MANAGEMENT, and this is what sets medical apart from other sectors. The risk management process run under ISO 14971 also determines which tests are required. The test list is not copied from a table of standards; it is derived and justified from the device's intended use, the nature and duration of patient contact, the use environment and foreseeable misuse.

Assessment consists of several separate bodies of work, each with its own set of standards. Biocompatibility runs through the ISO 10993 series, electrical device safety through the IEC 60601 series, sterilisation through ISO 11135/11137/17665, packaging through ISO 11607, software through IEC 62304 and usability through IEC 62366. The quality system (ISO 13485) is the framework that binds these together.

Which tests are required is determined by the device's CLASS and its MODE OF CONTACT WITH THE BODY. A product in brief contact with skin and an implant entering the bloodstream do not go through the same test set; the scope is set by a biological evaluation plan prepared under ISO 10993-1. That plan justifies in writing which endpoints are required and why the others are not.

Packaging and sterilisation are taken as seriously as the device itself in this field. For a sterile device the packaging is not a transport container but the barrier that maintains sterility; if the barrier is breached, the device is no longer sterile. Packaging processes are therefore validated and shelf life is supported by real-time ageing data.

For devices containing software, assessment shifts from testing towards PROCESS assurance. IEC 62304 defines which development and verification steps must be followed according to the safety class of the software; the evidence is the traceability of the development process. Testing software does not make it safe — the process record does.

The clinical side is a separate column of the technical file. Test reports show that the device is technically safe; clinical evaluation establishes that the device delivers the intended clinical benefit and that the benefit-risk balance is acceptable. Neither replaces the other.

Method groups in this field

Biocompatibility
Cytotoxicity, irritation, skin sensitisation, systemic toxicity, haemocompatibility, genotoxicity and local effects after implantation. The required endpoints are set by the ISO 10993-1 plan.
Electrical device safety
IEC 60601-1 basic safety and essential performance; EMC, alarm, usability and environmental requirements through the collateral standards.
Sterilisation validation
Validation of sterilisation processes by ethylene oxide, radiation or moist heat; bioburden and sterility assurance level studies.
Packaging
Integrity of the sterile barrier system, seal strength, distribution simulation and shelf-life studies.
Microbiological tests
Bioburden determination, sterility testing, bacterial endotoxin and, where required, carrier validation studies.
Software and usability
IEC 62304 life cycle evidence and use-error focused evaluation under IEC 62366.

Commonly confused in this field

Cytotoxicity alone is not evidence of biocompatibility; the required set of endpoints is determined and justified according to ISO 10993-1.
An ISO 13485 certificate does not confer CE marking; classification under the MDR, the technical file and the notified body process run separately.
Accelerated ageing does not replace real-time ageing; a shelf life claim is supported by real-time data.
A change of material (supplier, pigment, sterilisation method) may require the biological evaluation to be repeated; it is not a silent change.
An assessment made without the collateral and particular standards for IEC 60601-1 is incomplete; which -1-x and -2-x standards were applied must appear in the report.
In vitro diagnostic devices fall under the IVDR rather than the MDR, and laboratory equipment is often on the IEC 61010-1 side.

Which decisions these results support

MDR/IVDR technical file and notified body assessment
Completing the biological evaluation plan
Sterilisation and packaging validation
Determining shelf life and storage conditions
Determining the scope of reassessment after a design change

Related Tests

Frequently Asked Questions About Bioburden — ISO 11737-1

Why does bioburden affect the sterilisation dose?

Sterilisation reduces the microorganism count logarithmically. The higher the initial microorganism count, the higher the dose or longer the time needed to reach the same sterility assurance level (SAL). Bioburden is therefore a direct input to dose determination.

Why is recovery efficiency measured?

Not all microorganisms can be removed from the product. If the efficiency factor is not known, the true bioburden appears lower than it is, and the sterilisation dose is determined as inadequate; this is a direct safety risk.